Thierry Conroy

Thierry Conroy led the PRODIGE 24 trial establishing modified FOLFIRINOX as a superior adjuvant regimen versus gemcitabine alone for resected pancreatic adenocarcinoma, demonstrating a 20-month improvement in median overall survival. His landmark result transformed the adjuvant standard of care for fit patients with resected PDAC globally. He is the principal developer of the FOLFIRINOX regimen and led its application across multiple gastrointestinal cancers. Conroy leads the GERCOR French GI oncology cooperative group and has been a prolific contributor to pancreatic cancer clinical research.